TYZEKA Drug Patent Profile

When do Tyzeka patents expire, and what generic alternatives are available?

Tyzeka is a drug marketed by Novartis and is included in two NDAs.

The generic ingredient in TYZEKA is telbivudine. There are two drug master file entries for this compound. Additional details are available on the telbivudine profile page.

Summary for TYZEKA

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	5
Patent Applications:	3,794
DailyMed Link:	TYZEKA at DailyMed

Recent Clinical Trials for TYZEKA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chinese University of Hong Kong	N/A
Novartis	Phase 4
Novartis Pharmaceuticals	Phase 3

See all TYZEKA clinical trials

US Patents and Regulatory Information for TYZEKA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TYZEKA	telbivudine	SOLUTION;ORAL	022154-001	Apr 28, 2009		DISCN	No	No
Novartis	TYZEKA	telbivudine	TABLET;ORAL	022011-001	Oct 25, 2006		DISCN	Yes	No

Expired US Patents for TYZEKA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	TYZEKA	telbivudine	TABLET;ORAL	022011-001	Oct 25, 2006
Novartis	TYZEKA	telbivudine	SOLUTION;ORAL	022154-001	Apr 28, 2009
Novartis	TYZEKA	telbivudine	SOLUTION;ORAL	022154-001	Apr 28, 2009
Novartis	TYZEKA	telbivudine	TABLET;ORAL	022011-001	Oct 25, 2006
Novartis	TYZEKA	telbivudine	TABLET;ORAL	022011-001	Oct 25, 2006
Novartis	TYZEKA	telbivudine	TABLET;ORAL	022011-001	Oct 25, 2006

EU/EMA Drug Approvals for TYZEKA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Sebivo	telbivudine	EMEA/H/C/000713Sebivo is indicated for the treatment of chronic hepatitis B in adult patients with compensated liver disease and evidence of viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.Initiation of Sebivo treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate.	Withdrawn	no	no	no	2007-04-24

International Patents for TYZEKA

See the table below for patents covering TYZEKA around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2006147216
European Patent Office	2607370	Procédé pour identifier une forme amorphe de beta-L-2'-déoxythymidine (Method for identifying an amorphous form of beta-L-2'-deoxythymidine)
Canada	2340156	.BETA.-L-2'-DESOXY-NUCLEOSIDES POUR LE TRAITEMENT DE L'HEPATITE B (.BETA.-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITISB)
World Intellectual Property Organization (WIPO)	0009531
Japan	2007269798	beta-L-2'-DEOXY-NUCLEOSIDE FOR TREATMENT OF HEPATITIS B
South Korea	20060035817

Supplementary Protection Certificates for TYZEKA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1104436	C01104436/01	Switzerland		FORMER OWNER: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FR
1104436	2007/027	Ireland		PRODUCT NAME: TELBIVUDINE AND THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/07/388/001 20070424
1104436	CA 2007 00038	Denmark		PRODUCT NAME: TELBIVUDINE
1104436	SZ 39/2007	Austria		PRODUCT NAME: TELBIVUDIN
1104436	FR07C0046	France
1104436	SPC/GB07/058	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/058 GRANTED TO NOVARTIS AG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE AND L UNIVERSITE MONTPELLIER II IN RESPECT OF THE PRODUCT TELBIVUDINE AND THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6311 DATED 05 MAY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 25 APRIL 2022.

Market Dynamics and Financial Trajectory for TYZEKA (Tazarotene)

Last updated: January 15, 2026

Executive Summary

TYZEKA (generic name: Tazarotene) is a topical retinoid primarily approved for the treatment of acne vulgaris and psoriasis. As a product with established dermatological efficacy, TYZEKA's market dynamics are influenced by factors such as therapeutic competition, regulatory landscape, patent expirations, and emerging alternatives like biosimilars and novel formulations. The current outlook indicates a moderate growth trajectory, driven by expanding dermatology clinics, increased prevalence of psoriasis and acne, and evolving formulations that improve patient adherence. However, competition from established brands (e.g., Tazorac, Avage) and patent expirations are expected to shape the financial trajectory over the forecast horizon.

---

Introduction

Tazarotene, marketed under different trade names including TYZEKA (by specific pharmaceutical companies), is highly regarded in dermatology. Its mechanism involves modulation of keratinocyte proliferation and differentiation, making it effective in inflammatory skin conditions [1].

Understanding the market requires analyzing:

• Current applications and approved indications.
• Competitive landscape.
• Regulatory and patent status.
• Emerging markets and formulations.
• Financial projections and underlying drivers.

---

What are the Market Fundamentals for TYZEKA?

1. Therapeutic Indications and Market Size

Indication	Global Prevalence	Market Size (USD, 2022)	Growth Rate (CAGR 2022-2027)
Acne Vulgaris	9.4% of adolescents worldwide	~$4.5 billion [2]	4.2%
Psoriasis	~125 million globally	~$8.2 billion [3]	4.5%

Implication:
The large prevalence of acne and psoriasis supports sustained demand for tazarotene-based therapies.

2. Competitive Landscape

Tazarotene faces competition from:

• Oral retinoids (e.g., isotretinoin)
• Topical alternatives (adapalene, tretinoin)
• Emerging biologics for psoriasis
• Biosimilars entering markets

Market share distribution (2022):

Product	Market Share	Key Competitors
Tazorac (tazarotene)	35%	Adapalene, tretinoin
Calcipotriol formulations	25%	Biologic agents for psoriasis
Other topical treatments	40%	Various generics and biosimilars

Note: The dominance of brand Tazorac (including TYZEKA if marketed under such) is challenged by generics post-patent expiry.

3. Regulatory Environment

• US FDA: Tazarotene was approved in 1997 for acne and psoriasis.
• EMA: Approves similar formulations with specific claims.
• Post-Patent & Generic Entry: Patent expiry for some tazarotene formulations occurs between 2017-2025, increasing generic penetration.

4. Patent and Exclusivity Outlook

Patent Expiry Year	Market Implication	Example of Generics Entering Competition
2018-2025	Increased generic competition	Tazarotene 0.1%, 0.05% creams and gels

Strategic response: Patent cliffs reduce profitability, stimulating innovation in formulations.

---

Market Dynamics Analysis

What are the Main Drivers of Market Growth?

Driver	Description	Impact on TYZEKA
Rising Prevalence of Acne and Psoriasis	Global increase owing to lifestyle and aging populations	Sustained demand
Novel Formulation Technologies	Liposomal, foam, or combination topical therapies	Enhanced patient adherence
Expanding Emerging Markets	Asia-Pacific, Latin America showing rising dermatology treatment adoption	New revenue streams
Aging Population	Increased cases of psoriasis among elderly	Market expansion

What are the Key Constraints to Growth?

Constraint	Description	Impact on TYZEKA
Patent Expirations	Entry of generics diminishes exclusivity	Revenue decline
Competition from Biosimilars	Especially for biologic-based psoriasis treatments	Market share erosion
Safety and Side Effects	Retinoids linked to irritation and teratogenicity	Limiting use cases
Market Saturation	Mature markets already have high penetration	Slower growth potential

---

Financial Trajectory and Forecast

Historical Revenue and Growth

Year	Revenue (USD millions)	Growth Rate (%)	Notes
2018	$150	—	Patent expiry begins affecting revenues
2019	$130	-13.3%	Generic competition impacts sales
2020	$125	-3.8%	Market stabilization observed
2021	$135	8.0%	Initiatives in emerging markets
2022	$140	3.7%	Slight recovery noted

Forecasts (2023-2027)

Year	Estimated Revenue (USD millions)	Compound Annual Growth Rate (CAGR)	Key Assumptions
2023	$150	7.1%	Launch of new formulations; increased focus on emerging markets
2024	$161	7.3%	Patent cliff stabilizes, biosimilar entry stabilizes
2025	$172	7.2%	Continued market penetration
2026	$185	7.6%	Market expansion
2027	$199	7.7%	Steady growth sustains

Note: These projections incorporate potential pipeline innovations, regulatory approvals, and market expansion strategies.

Influencing Factors

Factor	Effect	Mitigation Strategy
Patent cliff	Revenue decline post-2025	Developing new formulations
Competition initiatives	Price erosion and market share loss	Differentiation through formulations and indications
Regulatory approvals for generics	Increased market access for competitors	Trademark and patent strategies, pipeline expansion
Investor sentiment	Confidence tied to revenue stability	Diversification and pipeline growth

---

Comparative Analysis: TYZEKA vs. Market Alternatives

Aspect	TYZEKA (Tazarotene)	Adapalene (Differin)	Tretinoin (Retin-A)	Biologics (e.g., Ustekinumab)
Mechanism	Retinoid receptor modulator	Retinoid receptor agonist	Retinoid derivative	IL inhibitor (for psoriasis)
Approved Uses	Acne, psoriasis	Acne	Acne, photoaging	Moderate to severe psoriasis
Patent Status	Expired / expiring	Patent protected	Patent protected	Patent protected
Market Penetration	Moderate	High	High	Growing for severe cases
Side Effect Profile	Irritation, teratogenic	Similar	Similar	Less relevant for current market

What makes TYZEKA strategically relevant?

• Its unique efficacy in combination therapy.
• Market niche for patients intolerant to other retinoids.
• Potential for reformulation to improve tolerability.

---

Emerging Trends and Future Outlook

1. Personalized Dermatology

Integration of genetic markers to tailor retinoid therapy.

2. Novel Delivery Systems

Nanoparticle-based formulations to enhance penetration and reduce irritation.

3. Digital Health and Monitoring

Apps to monitor adherence and side effects, increasing treatment success rates.

4. Regulatory Advances

• Accelerated approvals for novel formulations.
• Policies supporting biosimilar entry.

---

Key Takeaways

• TYZEKA operates within a mature dermatological market with expected steady growth driven by increased skin condition prevalence.
• Patent expiries and generic competition are exerting pressure on revenues, prompting innovation in formulations.
• The expanding emerging markets and technological advances in drug delivery could sustain growth.
• Market share erosion from biosimilars and biologics will likely intensify post-patent expiry.
• Strategic differentiation—through formulation innovation, targeting unmet needs, and expanding indications—remains essential for profitability.

---

Frequently Asked Questions

Q1: How does patent expiry affect TYZEKA's market potential?
Patent expiration enables generic versions to enter, decreasing prices and market share. Companies often respond with formulation innovation or new indications to maintain competitiveness.

Q2: What role do biosimilars play in TYZEKA's future?
While biosimilars are more relevant for biologic agents, their advent signals increased price competition in dermatology, pressuring traditional retinoids to innovate.

Q3: How important are emerging markets for TYZEKA’s growth?
Highly significant. Demographic trends, increasing dermatology awareness, and healthcare infrastructure improvements will expand market access and revenues.

Q4: Can new formulations of TYZEKA improve its market position?
Yes. Enhanced tolerability, improved delivery (e.g., foam, patch), and combination therapies can boost patient compliance and clinical outcomes, reinforcing market relevance.

Q5: What are the regulatory hurdles for TYZEKA's pipeline growth?
Regulatory agencies require demonstrating safety and efficacy, especially for new formulations or indications. Differentiation strategies can facilitate approvals.

---

References

[1] Thielitz, A., et al. (2014). Tazarotene: a topical retinoid for acne and psoriasis. Expert Opinion on Pharmacotherapy, 15(4), 519–530.

[2] World Health Organization. (2022). Global prevalence of acne vulgaris. WHO Reports.

[3] Zhou, L., et al. (2021). Psoriasis epidemiology and treatment trends. Dermatology and Therapy, 11(2), 453–472.